论文部分内容阅读
目的结缔组织病Connectivetissuedisease(STD)常出现呼吸系统损害,本文旨在探讨CTD患者呼吸肌受损情况对肺通气功能,肺换气功能的影响。方法实验组选自我院CTD患者86例,其中系统性硬皮病(progressivesystemicsclerosis,PSS)21例;系统性红斑狼疮(systemiclupuserythematosus,SLE)30例;皮肌炎(dermatomyositis,DM)35例。对照组20例均为健康自愿者。于入院后治疗前分别测定努力肺活量(FVC)一秒率(FEV1.0/FVC),峰流速(PEF),一氧化碳弥散量(DLOO)最大吸气压(PIMAX),最大呼气压(PEMAX)动脉血氧分压(PaO2),动脉血二氧化碳分压(PaCO2)。结果FVC、DLCO和PaO2CTD各组与对照组比较差异均有显著性(P<0.05或P<0.01);FEV1.0/FVCSLE组和DM组分别为69±8.9,54±13.1与对照组比较86±5.5差异有显著性(P<0.05￣0.01);PEFSLE组和DM组与对照组比较差异有非常显著性(P<0.01￣0.05)。PI-MAX:PSS组、SLE组和DM组分别为79±19.4、65±13.1、48±11.2与对照组且93±16.7比较差异有显著性(P<0.05￣0.01)。PEMAXPSS组、SLE组和DM组分别为37±8.9、35±10.3、23±9.8与对照组54±7.6比较差异有显著性(P<0.05￣0.01)。结论本组实验提示CTD病人存在肺通气功能、肺换气功能障碍同时有呼吸肌受损。CTD病人肺功能降低除肺纤维化因素外还与
Objective The connective tissue disease Connective tissue disease (STD) often respiratory damage, this paper aims to explore the CTD patients with respiratory muscle damage on pulmonary ventilation, pulmonary ventilation function. Methods The experimental group was selected from 86 patients with CTD in our hospital. There were 21 cases of systemic sclerosis (PSS), 30 cases of systemic lupus erythematosus (SLE) and 35 cases of dermatomyositis (DM). Control group of 20 patients were healthy volunteers. FVC, FEV1.0, FEF, PEF, PIMOO and PEMAX were measured before admission. After treatment, PaO2, PaCO2. Results There was significant difference between FVC, DLCO and PaO2CTD groups and the control group (P <0.05 or P <0.01). The FEV1.0 / FVCSLE group and DM group were 69 ± 8.9 and 54 ± 13.1 respectively ± 5.5 (P <0.05 ~ 0.01). There was significant difference between PEFSLE group and DM group and control group (P <0.01 ~ 0.05). PI-MAX: The PSS group, SLE group and DM group were 79 ± 19.4,65 ± 13.1,48 ± 11.2 compared with the control group and 93 ± 16.7, the difference was significant (P <0.05 ~ 0.01). PEMAXPSS group, SLE group and DM group were 37 ± 8.9,35 ± 10.3,23 ± 9.8 compared with the control group 54 ± 7.6, the difference was significant (P <0.05 ~ 0.01). Conclusion This group of experiments suggest that there is pulmonary ventilation in patients with CTD, pulmonary ventilation dysfunction with respiratory muscle damage at the same time. Pulmonary function in patients with CTD reduction in addition to pulmonary fibrosis factors